KCNA2 Epilepsy: Difference between revisions

No edit summary
No edit summary
Line 8: Line 8:


== Introduction ==
== Introduction ==
KCNA2 is a potassium (K+) channel located in the brain. '''KCNA2 epilepsy''' is caused by a variation (described as a mutation) in the '''KCNA2 gene''' (on chromosome 1p13) leading to a malfunction in the K+ channel.<ref name=":0">KCNA2 Epilepsy Organisation. What is KCNA2 Epilepsy. Available from: https://www.kcna2epilepsy.org/kcna2-epilepsy/what-is-kcna2-epilepsy/ (accessed 26 June 2023).</ref><ref>McGinn RJ, Von Stein EL, Stromberg JE, Li Y. Precision medicine in epilepsy. [https://www.sciencedirect.com/science/article/abs/pii/S1877117322000473 Progress in Molecular Biology and Translational Science]. 2022 Jan 1;190(1):147-88.</ref>  
KCNA2 is a voltage-gated potassium (K+) channel. Many of these channels are located in the central nervous system. Mutations occurring in K+ channel-coding genes cause different neurological diseases. '''KCNA2 epilepsy''' is caused by a variation in the '''KCNA2 gene''' (on chromosome 1p13) leading to a malfunction in the K+ channel.<ref name=":0">KCNA2 Epilepsy Organisation. What is KCNA2 Epilepsy. Available from: https://www.kcna2epilepsy.org/kcna2-epilepsy/what-is-kcna2-epilepsy/ (accessed 26 June 2023).</ref><ref>McGinn RJ, Von Stein EL, Stromberg JE, Li Y. Precision medicine in epilepsy. [https://www.sciencedirect.com/science/article/abs/pii/S1877117322000473 Progress in Molecular Biology and Translational Science]. 2022 Jan 1;190(1):147-88.</ref><ref>Syrbe S, Hedrich U, Riesch E, Djémié T, Müller S, Møller RS, Maher B, Hernandez-Hernandez L, Synofzik M, Caglayan HS, Arslan M. [https://www.researchgate.net/publication/273383158_De_novo_loss-_or_gain-of-function_mutations_in_KCNA2_cause_epileptic_encephalopathy De novo loss-or gain-of-function mutations in KCNA2 cause epileptic encephalopathy]. Nature genetics. 2015 Apr;47(4):393-9.</ref>  


This malfunction can be seen as:<ref name=":0" />
This malfunction can be seen as:<ref name=":0" />
Line 17: Line 17:


In all three malfunctions, epilepsy may be observed.  
In all three malfunctions, epilepsy may be observed.  
KCNA2 epilepsy can also be part of encephalopathy.<ref>Masnada S, Hedrich UB, Gardella E, Schubert J, Kaiwar C, Klee EW, Lanpher BC, Gavrilova RH, Synofzik M, Bast T, Gorman K. [https://www.researchgate.net/publication/320372444_Clinical_spectrum_and_genotype-phenotype_associations_of_KCNA2-related_encephalopathies Clinical spectrum and genotype–phenotype associations of KCNA2-related encephalopathies.] Brain. 2017 Sep 1;140(9):2337-54.</ref> Encephalopathy itself can be defined as a "... dysfunction of the level or contents of consciousness due to brain dysfunction and can result from global brain insults or focal lesions." <ref>Erkkinen MG, Berkowitz AL. [https://www.amjmed.com/article/S0002-9343(19)30571-6/fulltext A clinical approach to diagnosing encephalopathy]. The American Journal of Medicine. 2019 Oct 1;132(10):1142-7.</ref>


== Clinically Relevant Anatomy<br>  ==
== Clinically Relevant Anatomy<br>  ==
Line 26: Line 28:
Epileptic encephalopathy<ref>Syrbe S, Hedrich U, Riesch E, Djémié T, Müller S, Møller RS, Maher B, Hernandez-Hernandez L, Synofzik M, Caglayan HS, Arslan M. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380508/pdf/emss-62156.pdf De novo loss-or gain-of-function mutations in KCNA2 cause epileptic encephalopathy]. Nature genetics. 2015 Apr;47(4):393-9.</ref>
Epileptic encephalopathy<ref>Syrbe S, Hedrich U, Riesch E, Djémié T, Müller S, Møller RS, Maher B, Hernandez-Hernandez L, Synofzik M, Caglayan HS, Arslan M. [https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4380508/pdf/emss-62156.pdf De novo loss-or gain-of-function mutations in KCNA2 cause epileptic encephalopathy]. Nature genetics. 2015 Apr;47(4):393-9.</ref>


A definition of encephalopathy is "Encephalopathy refers to dysfunction of the level or contents of consciousness due to brain dysfunction and can result from global brain insults or focal lesions." <ref>Erkkinen MG, Berkowitz AL. [https://www.amjmed.com/article/S0002-9343(19)30571-6/fulltext A clinical approach to diagnosing encephalopathy]. The American Journal of Medicine. 2019 Oct 1;132(10):1142-7.</ref><br>  
<br>  


== Clinical Presentation  ==
== Clinical Presentation  ==

Revision as of 21:37, 28 June 2023

This article or area is currently under construction and may only be partially complete. Please come back soon to see the finished work! (28/06/2023)

Original Editor - User Name
Top Contributors - Lauren Heydenrych and Lucinda hampton

Introduction[edit | edit source]

KCNA2 is a voltage-gated potassium (K+) channel. Many of these channels are located in the central nervous system. Mutations occurring in K+ channel-coding genes cause different neurological diseases. KCNA2 epilepsy is caused by a variation in the KCNA2 gene (on chromosome 1p13) leading to a malfunction in the K+ channel.[1][2][3]

This malfunction can be seen as:[1]

  1. A gain of function - where the channel does not close properly. This leads to an increased amount of K+ in the brain.
  2. A loss of function - where the channel does not open properly. This leads to a low amount of K+ in the brain.
  3. A mix of functions - Where the K+ channel does both.

In all three malfunctions, epilepsy may be observed.

KCNA2 epilepsy can also be part of encephalopathy.[4] Encephalopathy itself can be defined as a "... dysfunction of the level or contents of consciousness due to brain dysfunction and can result from global brain insults or focal lesions." [5]

Clinically Relevant Anatomy
[edit | edit source]

add text here relating to clinically relevant anatomy of the condition

Mechanism of Injury / Pathological Process
[edit | edit source]

Epileptic encephalopathy[6]


Clinical Presentation[edit | edit source]

add text here relating to the clinical presentation of the condition

Diagnostic Procedures[edit | edit source]

add text here relating to diagnostic tests for the condition

Outcome Measures[edit | edit source]

add links to outcome measures here (see Outcome Measures Database)

Management / Interventions
[edit | edit source]

add text here relating to management approaches to the condition

Differential Diagnosis
[edit | edit source]

add text here relating to the differential diagnosis of this condition

Resources
[edit | edit source]

add appropriate resources here

References[edit | edit source]

  1. 1.0 1.1 KCNA2 Epilepsy Organisation. What is KCNA2 Epilepsy. Available from: https://www.kcna2epilepsy.org/kcna2-epilepsy/what-is-kcna2-epilepsy/ (accessed 26 June 2023).
  2. McGinn RJ, Von Stein EL, Stromberg JE, Li Y. Precision medicine in epilepsy. Progress in Molecular Biology and Translational Science. 2022 Jan 1;190(1):147-88.
  3. Syrbe S, Hedrich U, Riesch E, Djémié T, Müller S, Møller RS, Maher B, Hernandez-Hernandez L, Synofzik M, Caglayan HS, Arslan M. De novo loss-or gain-of-function mutations in KCNA2 cause epileptic encephalopathy. Nature genetics. 2015 Apr;47(4):393-9.
  4. Masnada S, Hedrich UB, Gardella E, Schubert J, Kaiwar C, Klee EW, Lanpher BC, Gavrilova RH, Synofzik M, Bast T, Gorman K. Clinical spectrum and genotype–phenotype associations of KCNA2-related encephalopathies. Brain. 2017 Sep 1;140(9):2337-54.
  5. Erkkinen MG, Berkowitz AL. A clinical approach to diagnosing encephalopathy. The American Journal of Medicine. 2019 Oct 1;132(10):1142-7.
  6. Syrbe S, Hedrich U, Riesch E, Djémié T, Müller S, Møller RS, Maher B, Hernandez-Hernandez L, Synofzik M, Caglayan HS, Arslan M. De novo loss-or gain-of-function mutations in KCNA2 cause epileptic encephalopathy. Nature genetics. 2015 Apr;47(4):393-9.